Polpharma Biologics announced the signing of a licensing agreement with the Brazilian company Libbs Farmacêutica. Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a biosimilar for autoimmune diseases in the rapidly growing Brazilian market.
Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmacêutica will hold an exclusive license for the commercialization, marketing and distribution of the biosimilar in Brazil. This collaboration opens up exciting new opportunities and demonstrates the shared commitment of both companies to delivering innovative and accessible therapies to patients.
“Entering the Brazilian market with a biosimilar is a significant step for Polpharma Biologics and reflects our ongoing mission to expand access to high-quality, affordable biological treatments worldwide,” said Anjan Selz, CEO of Polpharma Biologics. “Our collaboration with Libbs Farmacêutica, a company with deep knowledge of the Brazilian market, provides us with strong commercial expertise. Combined with our development and manufacturing capabilities, this partnership will significantly increase access to biological therapies for people in Brazil who are living with autoimmune diseases.”
"We currently treat more than 15 million patients with our products. This partnership with Polpharma Biologics is fully aligned with Libbs' strategy of investing in a diversified portfolio of medicines with potential to further expand the Brazilian population's access to healthcare," says Alcebíades de Mendonça Athayde Junior, CEO of Libbs.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!